Fannie Mae, Freddie Mac shares tumble after conservatorship comments
NEW YORK - Goldman Sachs & Co (NYSE:GS). LLC disclosed on Thursday that it has made recent transactions involving shares of Mural Oncology PLC. According to the details provided, the firm engaged in both long and short positions in the biotechnology company’s USD 0.01 ordinary shares.
On Wednesday, Goldman Sachs purchased a single share at a price of $2.5250, as reported in a disclosure to the Irish Takeover Panel. The financial institution’s dealings come amid the regulatory requirements for entities holding interests in relevant securities representing 1% or more.
The latest filing reveals that Goldman Sachs holds a long position of 90,971 shares (0.52%) and a short position of 183,666 shares (1.06%) in Mural Oncology. Additionally, the firm possesses 89,372 derivatives (0.51%) in the same class of relevant securities, albeit not in the form of options.
The disclosure also included a supplemental form indicating a purchased swap derivative related to one relevant security, with an exercise price of $0.0000 and an expiry date of July 8, 2025. No further details of the swap were provided, and the firm stated that there are no agreements, arrangements, or understandings related to the voting rights of any relevant securities under any options or derivatives.
The contact names provided for this disclosure were Papa Lette and Andrzej Szyszka, with contact numbers in France and Poland respectively. The information, based on a press release statement, is a regulatory requirement and is sourced from RNS, the news service of the London Stock Exchange (LON:LSEG).
Goldman Sachs’ engagement in Mural Oncology’s securities provides insight into the investment bank’s trading activities and positions within the biotech sector. The disclosed information is essential for investors monitoring the market movements and the interests of significant financial players in publicly traded companies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.